Security
LISATA THERAPEUTICS INC · CLBS
CLBSOTCCommon stockHistorical · closed Sep 14, 2022CIK 320017Updated Oct 20, 2026
Name history
Caladrius Biosciences, Inc. · through Sep 15, 2022CALADRIUS BIOSCIENCES, INC. · through Sep 15, 2022NeoStem, Inc. · through Jun 5, 2015PHASE III MEDICAL INC/DE · through Sep 1, 2006CORNICHE GROUP INC /DE · through Aug 14, 2003
Current security for this SEC filerLSTA · NASDAQ
CLBS price & chart
Historical security
This listing closed Sep 14, 2022. Live provider charts are shown only for current listings.
Current security: LSTA
About the company
Lisata Therapeutics is a clinical-stage pharmaceutical company. Following its acquisition of Marea Therapeutics, Lisata’s lead product candidate is MAR001, which is in Phase 2b clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels. The Company is also advancing MAR002 for the treatment of acromegaly. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. For more information on the Company, please visit www.lisata.com.
In the news
No coverage from other publishers is available.
Recent filings
ARS filing
DEF 14A filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
PRE 14A filing
D filing
Items 06b
Show 5 more recent filings
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Unregistered Sales of Equity Securities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 1.01, 2.01, 3.02, 5.02, 5.03, 7.01, 9.01
SCHEDULE 13G - filed by Branham Justin Earl regarding LISATA THERAPEUTICS, INC.
10-Q filing
Costs Associated with Exit or Disposal Activities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 2.05, 5.02, 8.01, 9.01
SC TO-T/A - filed by Kuva Labs, Inc. regarding LISATA THERAPEUTICS, INC.
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 21,759,000Source | 38,199,000Source | 11,027,000Source | 25,160,000Source | 42,571,000Source | 14,059,000Source | 28,981,000Source | 48,240,000Source | 35,002,000Source | 54,694,000Source | 73,034,000Source | 97,008,000Source |
| Property, Plant and Equipment, NetUSD | 22,000Source | 96,000Source | 14,000Source | 48,000Source | 119,000Source | 16,000Source | 74,000Source | 146,000Source | 72,000Source | 175,000Source | 296,000Source | 62,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 400,000Source | 400,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 18,998,000Source | 19,509,000Source | 10,443,000Source | 16,835,000Source | 28,293,000Source | 13,060,000Source | 20,217,000Source | 21,805,000Source | 16,209,000Source | 22,593,000Source | 32,154,000Source | 24,647,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 502,000Source | — | — | 501,000Source | — | — | 750,000Source | — | 900,000Source | — | — | — |
| Assets, CurrentUSD | 21,575,000Source | 37,692,000Source | 11,013,000Source | 24,885,000Source | 41,978,000Source | 14,020,000Source | 28,617,000Source | 47,559,000Source | 34,578,000Source | 53,924,000Source | 71,876,000Source | 96,182,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,075,000Source | 1,836,000Source | 570,000Source | 2,414,000Source | 3,716,000Source | 960,000Source | 2,034,000Source | 4,210,000Source | 2,433,000Source | 3,389,000Source | 2,650,000Source | 1,212,000Source |
| Operating Lease, Right-of-Use AssetUSD | 0Source | 182,000Source | — | 47,000Source | 225,000Source | — | 93,000Source | 267,000Source | 138,000Source | 308,000Source | 487,000Source | 724,000Source |
| Other Assets, NoncurrentUSD | 23,000Source | 201,000Source | 0Source | 70,000Source | 246,000Source | 23,000Source | 116,000Source | 290,000Source | 160,000Source | 332,000Source | 528,000Source | 764,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 4,640,000Source | 4,763,000Source | 3,037,000Source | 4,385,000Source | 4,576,000Source | 3,387,000Source | 3,879,000Source | 5,497,000Source | 5,685,000Source | 6,800,000Source | 6,710,000Source | 5,008,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 9,000Source | 8,000Source | 9,000Source | 9,000Source | 8,000Source | 9,000Source | 9,000Source | 8,000Source | 8,000Source | 8,000Source | 8,000Source | 60,000Source |
| Additional Paid in CapitalUSD | 579,812,000Source | 577,878,000Source | 581,030,000Source | 579,227,000Source | 577,552,000Source | 580,787,000Source | 578,923,000Source | 577,283,000Source | 578,418,000Source | 576,971,000Source | 574,548,000Source | 545,988,000Source |
| Retained Earnings (Accumulated Deficit)USD | -561,698,000Source | -543,456,000Source | -572,070,000Source | -557,449,000Source | -538,526,000Source | -569,141,000Source | -552,790,000Source | -533,482,000Source | -548,066,000Source | -528,081,000Source | -507,241,000Source | -453,016,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -42,000Source | -32,000Source | -17,000Source | -50,000Source | -77,000Source | -21,000Source | -78,000Source | -104,000Source | -81,000Source | -42,000Source | -29,000Source | -70,000Source |
| Stockholders' Equity Attributable to ParentUSD | 17,373,000Source | 33,690,000Source | 8,244,000Source | 21,029,000Source | 38,249,000Source | 10,926,000Source | 25,356,000Source | 42,997,000Source | 29,571,000Source | 48,148,000Source | 66,578,000Source | 92,254,000Source |
| Liabilities and EquityUSD | 21,759,000Source | 38,199,000Source | 11,027,000Source | 25,160,000Source | 42,571,000Source | 14,059,000Source | 28,981,000Source | 48,240,000Source | 35,002,000Source | 54,694,000Source | 73,034,000Source | 97,008,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 4,568,000Source | 4,691,000Source | 2,987,000Source | 4,313,000Source | 4,457,000Source | 3,315,000Source | 3,807,000Source | 5,333,000Source | 5,613,000Source | 6,590,000Source | 6,383,000Source | 4,523,000Source |
| Operating Lease, Liability, CurrentUSD | 0Source | 181,000Source | — | 47,000Source | 176,000Source | — | 92,000Source | 172,000Source | 137,000Source | 168,000Source | 180,000Source | 229,000Source |
| Accounts Payable, CurrentUSD | 619,000Source | 556,000Source | 836,000Source | 782,000Source | 728,000Source | 510,000Source | 602,000Source | 1,263,000Source | 1,284,000Source | 2,421,000Source | 2,655,000Source | 1,934,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 0Source | — | — | 47,000Source | — | — | 92,000Source | 0Source | 137,000Source | 305,000Source | 485,000Source |
| Other Liabilities, NoncurrentUSD | 72,000Source | 72,000Source | 50,000Source | 72,000Source | 119,000Source | 72,000Source | 72,000Source | 164,000Source | 72,000Source | 210,000Source | 327,000Source | 485,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -254,000Source | -254,000Source | -254,000Source | -254,000Source | -254,000Source | -254,000Source | -254,000Source | -254,000Source | -254,000Source | -254,000Source | -254,000Source | -254,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 3,949,000Source | 4,135,000Source | 2,151,000Source | 3,531,000Source | 3,729,000Source | 2,805,000Source | 3,205,000Source | 4,070,000Source | 4,329,000Source | 4,169,000Source | 3,728,000Source | 2,589,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 14,492,000Source | 30,301,000Source | — | 17,252,000Source | 33,829,000Source | — | 22,984,000Source | 39,221,000Source | 25,649,000Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | -4,249,000Source | -4,930,000Source | -2,929,000Source | -4,659,000Source | -5,044,000Source | -4,489,000Source | -4,724,000Source | -19,985,000Source | -20,840,000Source | -54,225,000Source | -27,466,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | 44,000Source | 42,000Source | 3,000Source | 44,000Source | 45,000Source | 2,000Source | 43,000Source | 174,000Source | 189,000Source | 69,000Source | 55,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 364,000Source | 530,000Source | 1,653,000Source | — | — | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 0Source | -150,000Source | 900,000Source | — | — | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -798,000Source | -2,330,000Source | -2,479,000Source | -1,508,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,083,000Source | -5,402,000Source | -19,356,000Source | -20,032,000Source | -21,170,000Source | -22,245,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 9,431,000Source | 13,233,000Source | 10,102,000Source | 28,911,000Source | -54,896,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 28,000Source | 0Source | 0Source | 285,000Source | 60,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 159,000Source | 243,000Source | 274,000Source | 91,000Source | 267,000Source | 248,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 181,000Source | -23,000Source | -206,000Source | 385,000Source | -224,000Source | 85,276,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -2,896,000Source | 4,008,000Source | -6,384,000Source | -9,561,000Source | 7,507,000Source | 8,135,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | 18,998,000Source | 19,509,000Source | 10,443,000Source | 16,835,000Source | 28,293,000Source | 13,060,000Source | 20,217,000Source | 16,209,000Source | 22,593,000Source | 32,154,000Source | 24,647,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 6,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 6,000Source | 2,000Source | -55,000Source | -16,000Source | -10,000Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | 232,000Source | 327,000Source | 214,000Source | 239,000Source | 237,000Source | 364,000Source | 530,000Source | 1,653,000Source | 2,038,000Source | 2,636,000Source | 2,005,000Source |
| Amortization of Intangible AssetsUSD | — | 18,000Source | 18,000Source | 0Source | 18,000Source | 18,000Source | 0Source | 17,000Source | 71,000Source | 21,000Source | 21,000Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 14,492,000Source | 30,301,000Source | — | 17,252,000Source | 33,829,000Source | — | 22,984,000Source | 25,649,000Source | — | — | — |
| DepreciationUSD | — | — | — | — | — | — | 2,000Source | 26,000Source | 100,000Source | 100,000Source | 100,000Source | 100,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | — | — | — | — | -11,000Source | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | -3,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | — | 3,408,000Source | 2,685,000Source | — | 3,738,000Source | 3,245,000Source | 12,075,000Source | — | — | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | 0Source | -30,000Source | — | 0Source | 0Source | — | 0Source | -130,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | 0Source | 0Source | 0Source | 0Source | 0Source | -387,000Source | -962,000Source | -798,000Source | -2,330,000Source | -2,479,000Source | -1,508,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | -4,249,000Source | -4,930,000Source | -2,929,000Source | -4,659,000Source | -5,044,000Source | -4,489,000Source | -4,724,000Source | -19,985,000Source | -20,840,000Source | -54,225,000Source | -27,466,000Source |
| Nonoperating Income (Expense)USD | — | 165,000Source | 406,000Source | 1,063,000Source | 209,000Source | 479,000Source | 66,000Source | 161,000Source | 1,626,000Source | 2,538,000Source | 897,000Source | 76,000Source |
| Operating ExpensesUSD | — | 4,414,000Source | 5,336,000Source | 3,992,000Source | 4,938,000Source | 5,523,000Source | 4,942,000Source | 5,847,000Source | 23,409,000Source | 25,708,000Source | 57,601,000Source | 29,050,000Source |
| Other Nonoperating Income (Expense)USD | — | -18,000Source | -45,000Source | 984,000Source | -7,000Source | -14,000Source | -54,000Source | -105,000Source | -257,000Source | -186,000Source | -155,000Source | -75,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 0Source | 212,000Source | 68,000Source | 321,000Source | 43,000Source | 85,500,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 124,000Source | 8,000Source | 0Source | 155,000Source | 0Source | 24,000Source |
income statement · annual statements
| Line item | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | 0Source | 0Source | 0Source | 70,000Source | 0Source | 0Source | 0Source | 1,000,000Source | 0Source | — | — |
| Selling, General and Administrative ExpenseUSD | — | 2,455,000Source | 2,794,000Source | — | 2,685,000Source | 2,922,000Source | — | 3,245,000Source | — | 12,974,000Source | 14,141,000Source | 11,370,000Source |
| Operating Income (Loss)USD | — | -4,414,000Source | -5,336,000Source | -3,992,000Source | -4,868,000Source | -5,523,000Source | -4,942,000Source | -5,847,000Source | -22,409,000Source | -25,708,000Source | -57,601,000Source | -29,050,000Source |
| Other Nonoperating Income (Expense)USD | — | -18,000Source | -45,000Source | 984,000Source | -7,000Source | -14,000Source | -54,000Source | -105,000Source | -257,000Source | -186,000Source | -155,000Source | -75,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | -4,249,000Source | -4,930,000Source | -2,929,000Source | -4,659,000Source | -5,044,000Source | -4,876,000Source | -5,686,000Source | -20,783,000Source | -23,170,000Source | -56,704,000Source | -28,974,000Source |
| Income Tax Expense (Benefit)USD | — | 0Source | 0Source | 0Source | 0Source | 0Source | -387,000Source | -962,000Source | -798,000Source | -2,330,000Source | -2,479,000Source | -1,508,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | -4,249,000Source | -4,930,000Source | -2,929,000Source | -4,659,000Source | -5,044,000Source | -4,489,000Source | -4,724,000Source | -19,985,000Source | -20,840,000Source | -54,225,000Source | -27,466,000Source |
| Earnings Per Share, BasicUSD per share | — | -0.49Source | -0.59Source | -0.32Source | -0.54Source | -0.61Source | -0.5Source | -0.55Source | -2.4Source | -2.58Source | -10.47Source | -0.5Source |
| Earnings Per Share, DilutedUSD per share | — | -0.49Source | -0.59Source | -0.32Source | -0.54Source | -0.61Source | -0.5Source | -0.55Source | -2.4Source | -2.58Source | -10.47Source | -0.5Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | 8,738,000Source | 8,321,000Source | 9,106,000Source | 8,605,000Source | 8,308,000Source | 9,006,000Source | 8,602,000Source | 8,329,000Source | 8,073,000Source | 5,180,000Source | 55,313,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | 8,738,000Source | 8,321,000Source | 9,106,000Source | 8,605,000Source | 8,308,000Source | 9,006,000Source | 8,602,000Source | 8,329,000Source | 8,073,000Source | 5,180,000Source | 55,313,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | 18,000Source | 18,000Source | 0Source | 18,000Source | 18,000Source | 0Source | 17,000Source | 71,000Source | 21,000Source | 21,000Source | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | 44,000Source | 42,000Source | 3,000Source | 44,000Source | 45,000Source | 2,000Source | 43,000Source | 174,000Source | — | — | 55,000Source |
| General and Administrative ExpenseUSD | — | — | — | 3,408,000Source | 2,685,000Source | — | 3,738,000Source | 3,245,000Source | 12,075,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -19,474,000Source | -21,477,000Source | -56,175,000Source | -28,974,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | 0Source | -30,000Source | — | 0Source | 0Source | — | 0Source | -130,000Source | — | — | — |
| Investment Income, NetUSD | — | 183,000Source | 451,000Source | 79,000Source | 216,000Source | 493,000Source | 120,000Source | 266,000Source | 1,883,000Source | 2,724,000Source | 1,052,000Source | 151,000Source |
| Nonoperating Income (Expense)USD | — | 165,000Source | 406,000Source | 1,063,000Source | 209,000Source | 479,000Source | 66,000Source | 161,000Source | 1,626,000Source | 2,538,000Source | 897,000Source | 76,000Source |
| Operating ExpensesUSD | — | 4,414,000Source | 5,336,000Source | 3,992,000Source | 4,938,000Source | 5,523,000Source | 4,942,000Source | 5,847,000Source | 23,409,000Source | 25,708,000Source | 57,601,000Source | 29,050,000Source |
| Research and Development ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 17,680,000Source |
Filing attachments
ef20083796_ex99-1.htm · 8-K · 2026-10-14
Exhibit 99.1 Lisata Therapeutics Appoints Jeff Farrow to Board of Directors Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee Liberty Corner, N.J., October 14, 2026 - Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026. Mr. Farrow fills a newly created seat, expan…
Read attachment ↗ef20082158_ex99-1.htm · 8-K · 2026-09-17
EX-99.1 7 ef20082158_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement Combined company to focus on developing first-in-class next Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and MAR002 for the treatment of acromegaly which is advancing to a Phase 2 study Concurrent financing of $225 million from leading li…
Read attachment ↗ef20082158_ex99-2.htm · 8-K · 2026-09-17
EX-99.2 8 ef20082158_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Marea TherapeuticsTransformative cardioendocrine therapies Confidential Forward Looking Statements & Disclaimers Confidential This presentation has been prepared by the Company based on information and data which the Company considers reliable, but no reliance shall be placed on, and no representation or warranty, express or implied, whatsoever is or will be given by the Company or any of its affiliates, directors, officers, employe…
Read attachment ↗ny20068687x1_ex107.htm · SC TO-T · 2026-06-10
Exhibit 107 Calculation of Filing Fee Table SCHEDULE TO (Form Type) LISATA THERAPEUTICS, INC. (Name of Subject Company (Issuer)) KUVA ACQUISITION CORP., (Offeror) A Direct Wholly-Owned Subsidiary of KUVA LABS INC. (Parent of Offeror) (Name of Filing Persons (identifying status as offeror, issuer or other person)) Table 1 - Transaction Valuation Transaction Valuation* Fee Rate Amount of Filing Fee** ─────────────────────────────────────…
Read attachment ↗ny20068687x4_ex99-1.htm · SC TO-C · 2026-06-01
Exhibit 99.1 FOR IMMEDIATE RELEASE Kuva and Lisata Therapeutics Tender Offer Update HOUSTON, TX - June 1, 2026 - As previously announced on May 29, 2026, Kuva Labs, Inc. (“Kuva” or “Parent”) and Lisata Therapeutics, Inc. (“Lisata”) (Nasdaq: LSTA), together with Kuva’s wholly owned subsidiary Kuva Acquisition Corp. (“Kuva Acquisition”), entered into an amendment (the “Amendment”) to the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among Kuva, Kuva Acquis…
Read attachment ↗ny20068687x3_ex99-1.htm · SC TO-C · 2026-05-29
Exhibit 99.1 FOR IMMEDIATE RELEASE Kuva and Lisata Therapeutics Amend Merger Agreement HOUSTON, TX - May 29, 2026 - On May 29, 2026, Kuva Labs, Inc. (“Kuva” or “Parent”) and Lisata Therapeutics, Inc. (“Lisata”) (Nasdaq: LSTA), together with Kuva’s wholly owned subsidiary Kuva Acquisition Corp. (“Kuva Acquisition”), entered into an amendment (the “Amendment”) to the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among Kuva, Kuva Acquisition and Lisata (the…
Read attachment ↗